Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of IT1208 in subjects with advanced or metastatic solid tumors

Next Previous
X
Search
Trial Profile

Phase I study of IT1208 in subjects with advanced or metastatic solid tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IT 1208 (Primary)
  • Indications Colon cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 03 Apr 2019 Results assessing changes in the T cell receptor (TCR) repertoire of blood and tumor biopsy samples following depletion of CD4+ cells by IT1208 in patients with gastrointestinal cancer, were presented at the 110th Annual Meeting of the American Association for Cancer Research.
    • 14 Sep 2018 Status changed from recruiting to completed.
    • 15 Mar 2017 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top